Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
about
How evidence-based are the recommendations in evidence-based guidelines?Discovery of novel GPVI receptor antagonists by structure-based repurposingMutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophyComparing angiotensin II receptor blockers on benefits beyond blood pressureMulticenter epidemiological studies of atherosclerosis imagingNoninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform?Serum uric acid and target organ damage in essential hypertensionBlood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010.Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in miceA combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.Interactions among related genes of renin-angiotensin system associated with type 2 diabetes.Antihypertensive medication exposure and cardiovascular outcomes in hemodialysis patients.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classificationClinical trials of antihypertensives: Nature of control and designGeographic variation in cardioprotective antihypertensive medication usage in dialysis patients.Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.Antihypertensive therapy: special focus on drug interactions.Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease.Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look.LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?Hypertension treatment and stroke prevention.Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).Current and future concepts in stroke prevention.Treatment of octogenarians: should we and how.Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.Angiotensin receptor blockade in the challenging era of systolic hypertension.Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly.Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists.Early and sustained blood pressure control is necessary for stroke prevention.Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.Diuretics for cardiovascular prevention in the elderly.Pulse pressure as a risk factor.Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage.Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.Hypertension 2005: an evidence-based approach to diagnosis and treatment - an American perspective.Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.
P2860
Q28469272-C7FB57CC-B522-438B-AC9F-DC626C3613D6Q28540147-D1708F59-A079-4CD1-BB39-30E6AB631FFEQ28771365-390258CE-E11A-43B2-AA3A-B740F207101BQ30360678-B484ABF4-539B-4B1E-BA48-407976C1C09FQ30477074-20CD9820-FC4E-479F-A9F9-01BDB0D43611Q30494287-6C1A9947-9045-4F64-A80F-482190D85DA7Q33583766-A67C580B-2EDF-463F-919A-6E3C4BA05624Q33789181-11D12318-7DE6-4C8C-B52B-904E36050A5BQ34017983-4A108391-A5E2-4F88-97AA-A055E0CCBA29Q34018990-579170FA-A4D3-4D1D-A9A5-8D099095FA73Q34153557-CADA174D-08CC-46E4-9D14-DD4B95304F06Q34244180-02C08F0D-E5C2-430F-B754-4BD3B566382FQ34299778-273596E4-4BE3-43C7-B69B-2C0CBAB8785AQ34455509-B68000F4-1B03-4E5D-8FDC-B72D2699BF85Q34569455-FBAA8BCA-DFD6-4E52-9046-C2708FC89E84Q34706443-C11E8DDD-30DB-4A83-90CE-5B0DB3EA73EBQ35120709-D6EE95A7-503D-49D7-87A5-1B7960912577Q35534909-F073E2E0-6052-4D03-B3B5-9391083F20F1Q35570981-416A3F53-1D3F-4664-A615-A60C788140F3Q35576079-E54B68A5-F59B-43AD-AC83-035F7BAF2BBEQ35581620-B9958196-9364-416A-A399-758461755A74Q35636620-5AA4CDEF-3DAC-4EDF-ABBF-7FEF14DD3221Q35649169-2B779DD3-4912-427C-A77A-07AE0EFD8CA4Q35690501-977E3863-C82E-4959-B0A9-2856B5AC4E33Q35722818-0B2905FF-C31D-4FE8-9EBE-1DB3E49DB602Q35767502-3F671942-6830-48BF-92CE-7C18016AD17CQ35820304-2DFDD21C-5018-4810-84FE-D7786700C618Q35866273-19DAEB6E-4B05-4987-8CA6-F040C55572A5Q35879105-9026A0AC-8C3C-4290-8498-47DC80E1E62CQ35905180-0EBA7605-6A2D-4902-BAA4-F3E490B2C0C8Q35909267-AA584135-F52A-475C-B16F-A6DB461B254EQ35925533-301C2384-E5C4-405A-989A-61F145E52D4AQ35980982-3DC12689-0BBD-4052-9480-7A849D160464Q36035817-83565A8D-F8E4-49F1-B138-E51E7568E130Q36060436-865EE20A-0471-4CF3-999E-EC125382C184Q36067015-CB7E74D8-231E-4EF8-A956-637BD0B5AE39Q36210252-1BF3DDE7-5ED9-4F29-9A52-E537BF1095E2Q36216844-1222808D-05B7-4994-A523-0FB6F28FF895Q36302833-842EE61E-0521-4543-80BC-07A4C808D9BAQ36425956-6CC20C08-8C58-40DC-889A-8E6098B77C14
P2860
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effects of losartan on cardiov ...... int Reduction (LIFE) substudy.
@en
Effects of losartan on cardiov ...... vention for Endpoint Reduction
@nl
type
label
Effects of losartan on cardiov ...... int Reduction (LIFE) substudy.
@en
Effects of losartan on cardiov ...... vention for Endpoint Reduction
@nl
prefLabel
Effects of losartan on cardiov ...... int Reduction (LIFE) substudy.
@en
Effects of losartan on cardiov ...... vention for Endpoint Reduction
@nl
P2093
P50
P921
P356
P1476
Effects of losartan on cardiov ...... int Reduction (LIFE) substudy.
@en
P2093
Frej Fyhrquist
Gareth Beevers
Hans Ibsen
Hans Wedel
Jonathan Edelman
Krister Kristianson
LIFE (Losartan Intervention for Endpoint Reduction) Study Group
Lars H Lindholm
Markku S Nieminen
Ole Lederballe-Pedersen
P304
P356
10.1001/JAMA.288.12.1491
P407
P577
2002-09-01T00:00:00Z